Toward standardized usage of the word serendipity in the historiography of psychopharmacology

Journal of the History of the Neurosciences

Volumn 19, Issue 3, 2010, Pages 253-270

  Baumeister, Alan A ^a   Hawkins, Mike F ^a   López Muñoz, Francisco ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

antidepressants; antipsychotics; anxiolytics; mood stabilizers; psychopharmacology; serendipity

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; DRUG DEVELOPMENT; HISTORY; HUMAN; MENTAL DISEASE; NOMENCLATURE; PSYCHOPHARMACOLOGY;

DRUG DISCOVERY; HISTORIOGRAPHY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; TERMINOLOGY AS TOPIC;

EID: 77954637806     PISSN: 0964704X     EISSN: 17445213     Source Type: Journal    
DOI: 10.1080/09647040903188205     Document Type: Article

References (58)

1. Arfwedson A (1818): Undersokning af nagra vid Utö Jernmalmsbrott forekommande Fossilier, och af ett deri funnet eget Eldfast Alkali. Afliandlingar I Fysick, Kemi och Minerologi 6:145-172.
2. Auwers K, von Meyenburg F (1891): Ueber eine neue Synthese von Derivaten des Isindazols. Ber Dtsch Chem Ges 24:2370-2388.
3. Ban TA (2006): The role of serendipity in drug discovery. Dialogues Clin Neurosci 8:335-344.
4. Baumeister AA, Hawkins MF, Uzelac SM (2003): The myth of reserpine-induced depression: Role in the historical development of the monoamine hypothesis. j Hist Neurosci 12:207-220.
5. Berger FM (1984): Anxiety and the discovery of the tranquillizers. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Baltimore, Ayd Medical Communications, pp. 115-129.
6. Berer FM, Bradley W (1946): The pharmacological properties of alpha, beta-dihydroxy-gama-(2-methylphenoxy)-propane (Myanesin). Br J Pharmacol 1:265-272.
7. Blackwell B (1970): The process of discovery. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, JB Lippincott Company, pp. 11-29.
8. Brodie BB, Pletscher AP, Shore, PA (1955): Evidence that serotonin has a role in brain function. Science 122:968.
9. Cade JFJ (1949): Lithium salts in the treatment of psychotic excitement. Med J Austral 2:349-352.
10. Cade JF (1970): The story of lithium. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, JB Lippincott Company, pp. 218-229.
11. Carlsson A (1959): The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11:490-493.
12. Carraz G, Darbon M, Lebreton S, Beriel H (1964): Proprietés pharmacodynamiques de l'acide ndipropylacétique etde ses dérivés. Therapie 19:469-475.
13. Cohen IM (1970): The benzodiazepines. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, JB Lippincott Company, pp. 130-141.
14. Comitè Lyonnais de Recherches Thérapeutiques en Psychiatrie (2000): The birth of psychopharmacology: Explorations in a new world - 1952-1968. In: Healy D, ed., The Psychopharmacologists, Vol. 3. London, Arnold, pp. 1-54.
15. Conrad M, Guthzeit M (1881): über Barbitursaure. Ber Dtsch Chem Ges 14:1943.
16. Crane G (1957): Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiat Res Rep 8:142-152.
17. Delay J, Deniker P, Harl JM (1952): Utilisation en therapeutique d'une phenotiazine d' action centrale selective (4560 RP). Ann Med Psychol 110:112-117.
18. Deniker P (1970): Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, JB Lippincott Company, pp. 155-164.
19. Divry P, Bobon J, Collard J (1958): Le R1625: Nouvelle therapeutique symptomatique de l'agitation psychomotrice. Acta Neurol Psychiatr Belg 58:878-888.
20. Fangmann P, Assion HJ, Juckel G, Alamo C, Lopez-Munoz F (2008): Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part II: Tricyclics and tetracyclics. J Clin Psychopharmacol 28:1-4.
21. Finger S (2000): Minds behind the Brain. A History of the Pioneers and their Discoveries. New York, Oxford University Press.
22. Fischer E, von Mering J (1903): Uber ein neue Klasse von Schlafmitteln. Therapie Gegenwart 44:97-101.
23. Garrod AB (1876): A Treatise on Gout and Rheumatic Gout (Rheumatoid Arthritis), 3rd ed. London, Longmans, Green R Co.
24. Hauptmann A (1912): Luminal bei Epilepsie. Munch Med Wochenschrift 59:1907.
25. Healy D (1997): The Antidepressant Era. Cambridge, Harvard University Press.
26. Healy D (1998): The Psychopharmacologists II. Philadelphia, Lippincott-Raven Publishers.
27. Healy D (2000): The Psychopharmacolo gists III. London, Arnold.
28. Hofmann A (1970): The discovery of LSD and subsequent investigations on naturally occurring hallucinogens. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry, Philadelphia, JB Lippincott Company, pp. 91-106.
29. Hofmann A (1983): LSD My Problem Child. Reflections on Sacred Drugs, Mysticism, and Science. Los Angeles, J. P. Tarcher.
30. Janssen, PAJ (1970): The butyrophenone story. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, JB Lippincott Company, pp. 165-179.
31. Janssen PAJ, Van de Westeringh C, Jageneau AHM, Demoen PJA, Hermans BKF, Van Daele GHP, Schellekens KH, Van der Eycken CA (1959): Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)- butyrophenone. Part I. Synthesis and screening data in mice. J Med Pharm Chem 1:281-297.
32. Jeste D, Gillin CG, Wyatt RJ (1979): Serendipity in biological psychiatry - A myth? Arch Gen Psychiatry 36:1173-1178.
33. Johnson FN (1984): The History of Lithium Therapy. London, The Macmillan Press Ltd.
34. Klein DF (2008): The loss of serendipity in psychopharmacology. J Am Med Assoc 299:1063-1065.
35. Kline NS (1954):. Use of Rauwolfia serpentina benth in neuropsychiatric conditions. Ann NY Acad Sci 59:107-132.
36. Kuhn R (1957): über die Behandlung depressiver Zustände mit einem Iminodibenzyl-derivat (G22355). Schweiz Med Wochenschr 87:1135-1140.
37. Kuhn R (1970): The imipramine story. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, JB Lippincott Company, pp. 205-217.
38. Laborit H, Huguenard P (1951): L'hibernation artificielle par moyens pharmacodynamiques ou physiques. Press Méd 59:1329.
39. Lambert PA, Cavaz G, Borselli S, Carrel S (1966): Action neuropsychotrope d'un nouvel antiepileptique: le Dépamide. Ann Méd Psychol 1:707-710.
40. Lewis WS (1960): Horace Walpole's Correspondence, Vol 20. London, Oxford University Press.
41. López-Muñoz F, Alamo C (2009): The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull 79:130-141.
42. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G (2005a): History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17:113-135.
43. López-Muñoz F, Ucha-Udabe R, Alamo C (2005b): The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 1:329-343.
44. López-Muñoz F, Alamo C, Juckel G, Assion HJ (2007): Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part I: Monoamine oxidase inhibitors. J Clin Psychopharmacol 27:555-559.
45. Ludwig BJ, Piech EC (1951): Some anticonvulsant agents derived from 1,3-propanediol. J AmChem Soc 73:5779-5781.
46. Merton RK, Barber E (2004): The Travels and Adventures of Serendipity. Princeton, Princeton University Press.
47. Meunier H, Carraz G, Meunier Y, Aymard M (1963): Propriétés pharmacodynamiques de l'acide n-dipropylacétique. I. Propriétés antiépiletiques. Thérapie 18:435-438.
48. Pressman JD (1998). Last Resort: Psychosurgery and the Limits of Medicine. Cambridge, Cambridge University Press.
49. Ramchandani D, López-Muñoz F, Alamo C (2006): Meprobamate: Tranquilizer or anxiolytic? A historical perspective. Psychiatr Quart 77:43-53.
50. Randall LO, Schallek W, Heise GA, Keith EK, Bagdon RE (1960): The psychosedative properties of methaminodiazepoxide. J Pharmacol Exp Ther 129:163-171.
51. Robitzek EF, Selikoff IJ, Ornstein GG (1952): Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Quart Bull Sea View Hospital 13:27-51.
52. Schou M (1968): Special review of lithium in psychiatric therapy and prophylaxis. J Psychiat Res 6:67-95.
53. Sternbach LH (1983): The Benzodiazepine Story. Basle, F. Hoffmann-La-Roche & Co.
54. Sternbach LH, Reeder E (1961): Quinazolidines and 1,4-Benzodiazepines IV. Transformations of 7-Chloro-2-methyamino-5-phenyl-3H-l, 4-benzodiazepine 4-Oxide. J Org Chem 26(12):4936-4941.
55. Swazey J P (1974): Chlorpromazine in Psychiatry. A Study of Therapeutic Innovation. Cambridge, The MIT Press.
56. Thuillier J (1999): Ten Years that Changed the Face of Mental Illness. London, Martin Dunitz Ltd.
57. Valenstein ES (1998): Blaming the Brain. New York, The Free Press.
58. Zeller, EA, Barsky J, Fouts JR, Kirch-Heimer WJ, Orden van LS (1952): Influence of isonicotinic acid hydrazide (IHN) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 8:349-350.